Health-Related Quality of Life of Patients with HIV/AIDS in Bogotá, Colombia
Background There has rarely been any reporting on health-related quality of life (HRQOL) of patients with HIV/AIDS in developing countries. Objectives To estimate the health utilities of people with HIV/AIDS in Bogotá, Columbia. Methods A cross-sectional survey was conducted for 181 patients receivi...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2016
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/18821
- Acceso en línea:
- http://repository.urosario.edu.co/handle/10336/18821
- Palabra clave:
- Aids
Burden
Colombia
Eq-5D-5L
Hiv
Quality Of Life
Utility
Acquired Immune Deficiency Syndrome
Adult
Age
Anxiety
Article
Cd4 Lymphocyte Count
Colombia
Cross-Sectional Study
Depression
Disease Classification
Disease Severity
Euroqol Five Dimensional Questionnaire
Euroqol Visual Analogue Scale
Female
Highly Active Antiretroviral Therapy
Human
Human Immunodeficiency Virus Infection
Major Clinical Study
Male
Pain
Priority Journal
Quality Of Life
Sex Difference
- Rights
- License
- Abierto (Texto completo)
Summary: | Background There has rarely been any reporting on health-related quality of life (HRQOL) of patients with HIV/AIDS in developing countries. Objectives To estimate the health utilities of people with HIV/AIDS in Bogotá, Columbia. Methods A cross-sectional survey was conducted for 181 patients receiving antiretroviral therapy from an outpatient HIV/AIDS clinic in Bogotá. The five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L) and the EuroQol visual analogue scale (EQ-VAS) were used to estimate HRQOL scores. To derive utilities on the basis of the EQ-5D-5L, the Spanish value set was used. Subgroup analyses were performed according to sex, age, the Centers for Disease Control and Prevention classification, and CD4 cell count. Results The mean utility of the EQ-5D-5L was estimated at 0.85 ± 0.21 and the EQ-VAS score was estimated at 84 ± 14. Pain/discomfort and anxiety/depression were the two EQ-5D-5L dimensions associated with the poorer outcomes. Subgroup analyses revealed significantly higher utilities (using the EQ-5D-5L) for men than for women (0.88 vs. 0.76; P = 0.002) and lower utilities for patients with severe HIV (0.83 for CD4 <200 vs. 0.87 for CD4 ≥ 500; P = 0.024). Conclusions The HRQOL scores of patients with HIV/AIDS receiving antiretroviral therapy were relatively high in Bogotá, Colombia, using the EuroQol questionnaire. The utility data could be useful, in combination with cost data, for future economic evaluations. © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) |
---|